11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Top Cited Papers
- 1 March 2010
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 9 (4), 363-372
- https://doi.org/10.1016/s1474-4422(10)70043-0
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseNeurology, 2009
- Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's diseaseBrain, 2009
- Immunotherapy Reduces Vascular Amyloid- in PDAPP MiceJournal of Neuroscience, 2008
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's diseaseBrain, 2008
- In VitroCharacterization of Pittsburgh Compound-B Binding to Lewy BodiesJournal of Neuroscience, 2007
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Functional Disability in Alzheimer's DiseaseInternational Psychogeriatrics, 1997
- The Neuropsychiatric InventoryNeurology, 1994
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984